IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4355
Positioning
Market Dominance
Mining
Non-Metallic And Industrial Metal Mining
$0
Anastasios Arima
IperionX Limited engages in the development of its mineral properties in the United States. It holds a 100% interest in the critical minerals Titan project, which has resources of titanium, zircon, and rare earth mineral resources in Tennessee, the United States. The company also engages in the production of angular and spherical titanium metal powders. It serves automotive and transport, consumer electronics, aerospace and defense, energy, medical, luxury goods, and industrial markets. The company was formerly known as Hyperion Metals Limited and changed its name to IperionX Limited in February 2022. IperionX Limited was incorporated in 2017 and is headquartered in Charlotte, North Carolina.
Headcount
—
HQ Base
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$VALE Vale S.A. | 75 | 88 | 93 | 67 | - | - | 15.8% | 6.9% | 36.6% | 22.8% | 15.9% | -8.9% | 0.0% | 0.0x | $38.7B | VS | |
$SU SUNCOR ENERGY INC | 74 | 87 | 90 | 53 | - | - | 13.1% | 6.5% | 58.3% | 18.4% | 11.0% | -3.6% | 4.9% | 29.0x | $46.0B | VS | |
$TRX TRX GOLD Corp | 72 | 83 | 77 | 96 | - | - | 10.7% | 6.1% | 41.5% | 27.8% | 11.4% | 40.0% | 0.0% | 2.0x | $104M | VS | |
$ORLA Orla Mining Ltd. | 72 | 94 | 83 | 78 | - | - | 19.6% | 15.7% | 74.8% | 47.5% | 26.2% | 47.2% | 0.0% | 0.0x | $1.7B | VS | |
$KGC KINROSS GOLD CORP | 71 | 83 | 89 | 79 | - | - | 15.1% | 9.3% | 37.8% | 31.6% | 20.0% | 21.3% | 1.3% | 21.0x | $11.4B | VS | |
$AEM AGNICO EAGLE MINES LTD | 71 | 80 | 80 | 71 | - | - | 9.4% | 6.5% | 60.5% | 36.0% | 22.9% | 25.0% | 2.0% | 6.0x | $38.9B | VS | |
$RIO RIO TINTO PLC | 70 | 76 | 84 | 64 | - | - | 20.3% | 11.2% | 23.0% | 20.1% | 23.1% | -1.3% | 11.2% | 26.0x | $93.8B | VS | |
$IAG IAMGOLD CORP | 70 | 71 | 82 | 89 | - | - | 29.9% | 17.1% | 33.7% | 57.8% | 51.9% | 65.4% | 0.0% | 34.0x | $2.5B | VS | |
$NGD New Gold Inc. /FI | 70 | 76 | 67 | 92 | - | - | 11.1% | 4.8% | 52.8% | 19.7% | 11.1% | 17.5% | 0.0% | 38.0x | $1.7B | VS | |
$PDS PRECISION DRILLING Corp | 70 | 77 | 90 | 65 | - | - | 6.6% | 3.6% | 34.4% | 11.0% | 5.9% | -10.0% | 0.0% | 52.0x | $876M | VS | |
$IPX IPERIONX Ltd | 32 | 13 | 25 | 44 | - | - | -153.0% | -134.6% | -178.1% | -995.6% | -995.6% | 550.3% | - | 4.0x | $0 | ||
| SECTOR BENCH | - | - | - | - | - | 13.7x | 5.2x | 4.0% | 3.9% | 43.2% | 12.2% | 6.2% | 2.6% | 0.0% | 0.3x | - | REF |
IPERIONX Ltd (IPX) receives a "Avoid" rating with a composite score of 32.3/100. It ranks #4355 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Anastasios Arima
Chief Executive Officer
13
34
28
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for IPX
CHARLOTTE, North Carolina
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Mining sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for IPX.
View All RatingsInsufficient data for Financial Analysis
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 13 | 1 | +12ALPHA |
| MOMENTUM | 44 | 46 | -2NEUTRAL |
| VALUATION | 25 | 15 | +10ALPHA |
| INVESTMENT | 34 | 38 | -4NEUTRAL |
| STABILITY | 28 | 19 | +9ALPHA |
| SHORT INT | 50 | 58 | -8DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -153.0% (sector 4.0%)
GM -178% vs sector 43%, OM -996% vs sector 12%
Capital turnover N/A, R&D intensity 454.1%
Rev growth 550%, 2yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags IPERIONX Ltd with an Avoid rating, assigning a composite score of 32.3/100 and 1 out of 5 stars. Ranked #4355 of 7,333 stocks, IPX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
IPERIONX Ltd registers a weak quality score of just 13/100, indicating significant profitability challenges. The company reports a return on equity of -153.0% (sector avg: 4.0%), gross margins of -178.1% (sector avg: 43.2%), net margins of -995.6% (sector avg: 6.2%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
IPX registers a value score of just 25/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 15.36x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
IPERIONX Ltd's investment score of 34/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 550.3% vs. a sector average of 2.6% and a return on assets of -134.6% (sector: 3.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
IPX is currently showing below-average momentum at 44/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 550.3% year-over-year, while a beta of 1.21 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
IPX's stability score of 28/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.21 and a debt-to-equity ratio of 4.00x (sector avg: 0.3x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 50/100 for IPX suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.21), elevated leverage (D/E: 4.00x), micro-cap liquidity risk. With a $0 market cap (micro-cap), IPERIONX Ltd may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
IPERIONX Ltd is a micro-cap company in the Mining sector, ranked #0 of 50 in its sector (100th percentile) and #4355 of 7,333 overall (41st percentile). Key comparisons include ROE of -153.0% trailing the 4.0% sector median and operating margins of -995.6% below the 12.2% sector average. This top-quartile standing reflects exceptional competitive strength relative to Mining peers.
While IPX currently exhibits a AVOID profile, superior opportunities exist within the MINING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Mining Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (13) would have the largest impact on the composite score.
ROE 3962% BELOW SECTOR MEDIAN
Gross Margin 512% BELOW SECTOR MEDIAN
Op. Margin 8240% BELOW SECTOR MEDIAN
AUDIT DATA AS OF JUN 30, 2025 (Q1 FY2025)
We rate IPERIONX Ltd (IPX) as Avoid with a composite score of 32.3/100 at a current price of $46.55. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (44th percentile) and investment (34th percentile), which together account for the majority of the composite score. Offsetting weakness in quality (13th percentile) and value (25th percentile) tempers our overall conviction. We assign a No Moat rating (34/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: sustainability of the current growth rate; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is widening, which provides additional comfort in the durability of the competitive position.
IPERIONX Ltd holds a top-quartile position (#0 of 50) within the Mining sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 32.3/100 places it at rank #4355 in our full 7,333-stock universe. At N/A in market capitalization, IPERIONX Ltd is a small-cap player in the Mining space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 550%, though momentum at the 44th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of -178% (-221.3pp vs sector) narrow to operating margins of -996% (-1007.8pp vs sector) and net margins of -995.6%, yielding a gross-to-net conversion rate of N/A%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $46.55, IPERIONX Ltd is trading at a premium to fundamental value. Our value factor score of 25/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 15.4x, P/S of 100.0x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Revenue growth of 550% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (4% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 32.3/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -995.6% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Below-average quality (13th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Very High uncertainty rating to IPERIONX Ltd. The stock exhibits multiple compounding risk factors: current negative profitability (net margin -995.6%), below-average price stability (28th percentile), weak quality scores (13th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: current negative profitability (net margin -995.6%); below-average price stability (28th percentile); weak quality scores (13th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 28th percentile and quality factor at the 13th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (4% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate IPERIONX Ltd's capital allocation as Poor. Key concerns include low returns on equity (-153.0%), negative profitability, weak asset returns (ROA -134.6%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — IPERIONX Ltd significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, IPERIONX Ltd receives a Avoid rating with a composite score of 32.3/100 (rank #4355 of 7,333). Our quantitative framework assigns a No Moat (34/100, trend: widening), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 29/100.
Our analysis does not support a constructive view on IPERIONX Ltd at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign IPERIONX Ltd a meaningful economic moat, scoring 34/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 13/20.
The strongest moat sources are growth durability (13/20) and reinvestment efficiency (9.7/20). Rev growth 550%, 2yr history. Capital turnover N/A, R&D intensity 454.1%. These pillars form the core of IPERIONX Ltd's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include margin superiority (0.8/20) and economic value creation (3.1/20). GM -178% vs sector 43%, OM -996% vs sector 12%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Widening. ROIC has trended upward at ~38.2pp per year, and operating margin trajectory confirms strengthening economics. IPERIONX Ltd's competitive position is improving on a fundamental basis. We expect the moat score to drift upward if these trends persist over the next 12–18 months.
Key profit drivers include robust top-line growth of 550% expanding the revenue base. The margin cascade from -178% gross to -996% operating to -995.6% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 13th percentile.
The margin profile shows gross margins of -178%, operating margins of -996%, net margins of -995.6%. Return metrics include ROE of -153.0% and ROA of -134.6%. Relative to the Mining sector, gross margins are 221.3 percentage points below the sector median of 43%, and ROE of -153.0% compares to a sector median of 4.0%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 4%, revenue growth of 550%. The sector median D/E is 0%, putting IPERIONX Ltd at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Gainers WeTrade Group, Inc. (NASDAQ: WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing models to increase product applications in the field of artificial intelligence. Cyxtera Technologies, Inc. (NASDAQ: CYXT) shares climbed 71.5% to $0.0717 after dropping 12% on Tuesday. Blue Water Biotech, Inc. (NASDAQ: BWV) gained 67% to $1.32 after the company acquired six FDA-approved drugs across various treatment areas WiSA Technologies, Inc. (NASDAQ: WISA) shares surged 51.7% to $1.9575. WiSA Technologies started taking pre-orders for WiSA E multichannel audio development kits. NextDecade Corporation (NASDAQ: NEXT) gained 35% to $6.93 after the company announced it has entered into framework agreements with Global Infrastructure Partners and TotalEnergies to support the development of the Rio Grande LNG project. Ideanomics, Inc. (NASDAQ: IDEX) rose 27.6% to $0.1177. Inventiva S.A. (NASDAQ: IVA) shares climbed 22.3% to $4.49 after the company announced its Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD achieved its primary efficacy endpoint. Greenidge Generation Holdings Inc. (NASDAQ: GREE) gained 21.3% to $1.93. Coherent Corp. (NYSE: COHR) surged 17% to $50.13. Leju Holdings Limited (NYSE: LEJU) rose 16.9% to $2.9699. IPG Photonics Corporation (NASDAQ: IPGP) climbed 16.1% to $135.92. Raymond James upgraded IPG Photonics from Market Perform to Outperform and announced a $170 price target. Akoya Biosciences, Inc. (NASDAQ: AKYA) gained 15.5% to $7.57. Gossamer Bio, Inc. (NASDAQ: GOSS) surged 13.6% to $1.3410. Microvast Holdings, Inc. (NASDAQ: MVST) jumped 12.7% to $1.7698. T2 Biosystems, Inc. (NASDAQ: TTOO) shares gained 11.7% to $0.0696. T2 Biosystems recently reported a clinical collaboration with Vanderbilt University Medical Center to implement and evaluate the T2Bacteria panel for clinical use. Nikola Corporation (NASDAQ: NKLA) rose 9.4% to $1.00 after jumping over 19% on Tuesday. Matterport, Inc. ...
Gainers Cyxtera Technologies, Inc. (NASDAQ: CYXT) shares rose 134.6% to $0.0981 in pre-market trading after dropping 12% on Tuesday. WiSA Technologies, Inc. (NASDAQ: WISA) shares surged 44.2% to $1.86 in pre-market trading. WiSA Technologies started taking pre-orders for WiSA E multichannel audio development kits. T2 Biosystems, Inc. (NASDAQ: TTOO) shares gained 32% to $0.0822 in pre-market trading. T2 Biosystems recently reported a clinical collaboration with Vanderbilt University Medical Center to implement and evaluate the T2Bacteria panel for clinical use. Oncorus, Inc. (NASDAQ: ONCR) gained 27.5% to $0.0931 in pre-market trading after declining around 10% on Tuesday. The company’s board of directors approved liquidation and it will be suspended from NASDAQ from 20 June. Inventiva S.A. (NASDAQ: IVA) gained 24% to $4.55 in pre-market trading after the company announced its Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD achieved its primary efficacy endpoint. Agile Therapeutics, Inc. (NASDAQ:
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares gained 143% to $2.77 after the company achieved its enrollment target for its adrulipase Phase 2 SPAN trial for exocrine pancreatic insufficiency in cystic fibrosis patients. IperionX Limited (NASDAQ: IPX) shares surged 92.6% to $12.69. IperionX agreed a Scope of Work for the supply of titanium metal components for Ford Motor Company using IperionX's unique 100% recycled, low-carbon titanium metal. Ideanomics, Inc. (NASDAQ: IDEX) gained 30% to $0.0820. On June 2, Ideanomics, received letter from Nasdaq indicating co was no longer in compliance with Independent Director, Audit Committee requirements. Cepton, Inc. (NASDAQ: CPTN) gained 26% to $0.6700. The OLB Group, Inc. (NASDAQ: OLB) shares climbed 25.8% to $0.8427. The company, last month, posted downbeat quarterly results. Allego N.V. (NYSE: ALLG) gained 24.2% to $3.49. Sonic Foundry, Inc. (NASDAQ: SOFO) climbed 23% to $1.07. Millennium Group International Holdings Limited (NASDAQ: MGIH) gained 23% to $2.4550. The OLB Group, Inc. (NASDAQ: OLB) climbed 21.4% to $0.8136. Evoke Pharma, Inc. (NASDAQ: EVOK) gained 20.5% to $1.88. YS Biopharma Co., Ltd. (NASDAQ: YS) shares rose 18.6% to $1.47 after dropping over 7% on Monday. YS Biopharma's PIKA Rabies Vaccine recently received Phase 3 clinical trial approval from Philippines FDA. Cohen & Company Inc. (NYSE: COHN) gained 18.5% to $3.97. Dave & Buster's Entertainment, Inc. (NASDAQ: PLAY) surged 16.9% to $45.17. Dave & Buster's Entertainment recently reported better-than-expected first-quarter EPS results. Akoya Biosciences, Inc. (NASDAQ: AKYA) climbed 16.9% to $6.36. Eastside Distilling, Inc. (NASDAQ: EAST) rose 16.9% to $3.94 after gaining 5% on ...
U.S. stocks traded mixed this morning, with Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.32% to 34,101.52 while the NASDAQ rose 0.16% to 13,594.96. The S&P 500, also rose, gaining, 0.19% to 4,377.22. Check This Out: Bitcoin Falls Below $26,000 Ahead Of Fed's Decision; XRP Becomes Top Loser Leading and Lagging Sectors Energy shares jumped by 0.9% on Wednesday. Meanwhile, top gainers in the sector included NextDecade Corporation (NASDAQ: NEXT), up 49%, and Ardmore Shipping Corporation (NYSE: ASC), up 4%. In trading on Wednesday, health care shares fell by 0.8%. Top Headline Producer prices for final demand fell 0.3% month-over-month in May versus a 0.2% increase in April, and compared to market expectations for a 0.1% decline. Equities Trading UP WeTrade Group, Inc. (NASDAQ: WETG) shares shot up 113% to $17.99. WeTrade launched large-scale language processing models to increase product applications in the field of artificial intelligence. Shares of NextDecade Corporation (NASDAQ: NEXT) got a boost, shooting 50% to $7.71 after the company announced it has entered into framework agreements with Global Infrastructure Partners and TotalEnergies to support the development of the Rio Grande LNG ...
Above 50MA
37.18%
Net New Highs
+51081